MSN Labs enters into Licensing Agreement with Lilly to launch Baricitinib (BARIDOZ) in India for COVID 19

New Delhi: MSN Labs (MSN) announced today, that they have entered into a royalty free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for COVID-19 in India.

 

The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

 

Dr. MSN Reddy, CMD – MSN Group, commented “This Collaboration with Eli Lilly and Company is a landmark milestone in India’s fight against COVID-19 and will thus help in increasing the availability and affordability of baricitinib”.

 

MSN will be launching the product under the brand name BARIDOZ in two strengths 2 mg & 4mg. MSN has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.

 

As part of the COVID treatment range, MSN has already launched FAVILOW (Favipiravir) in the strengths of 200mg, 400mg & 800mg and OSELOW (Oseltamivir) as 75 mg capsules.

 

Comments are closed.